1.
$Hims & Hers Health Inc.(HIMS)$ won’t fix this overnight -- but the path forward is clear if CEO is willing to take the following steps:
• Shift GLP-1s to 503B to eliminate regulatory risk
• Disclose safety protocols & bring in third-party medical oversight
• Pause aggressive GLP-1 marketing until controls are in place
• Reopen pharma partnerships to rebuild institutional trust
• Reframe the brand around trust & clinical legitimacy -- not speed
Image
2.
Despite $Tesla Motors(TSLA)$ successful Robotaxi launch in Austin, Polymarket still only prices +180 odds -- a 36% chance -- that California sees a rollout by year-end 2025.
The tech may be ready -- but the market’s betting that regulatory friction is far from over.
Image
For whom haven't open CBA can know more from below:
🏦 Open a CBA today and enjoy privileges of up to SGD 20,000 in trading limit with 0 commission. Trade SG, HK, US stocks as well as ETFs unlimitedly!
Find out more here:
Comments